TEVA PHARMACEUTICAL INDUSTRIES LIMITED

Their core work

Teva is one of the world's largest generic and specialty pharmaceutical companies, headquartered in Israel. Within H2020, they contribute industry-scale drug development expertise, real-world clinical data, and pharmacovigilance capabilities to large public-private research consortia. Their participation spans neurodegenerative diseases, pain management, clinical trial innovation, and medication safety — reflecting their commercial portfolio in CNS and specialty therapeutics. They bring the perspective and datasets of a major pharma manufacturer to collaborative research, particularly through IMI (Innovative Medicines Initiative) partnerships.

What they specialise in

How they've shifted over time

In the early period (2017–2018), Teva's H2020 engagement centered on preclinical data quality, pain therapeutics with deep phenotyping, and biomarker discovery — classic pharma R&D themes. From 2019 onward, their focus shifted markedly toward digital health tools (mobility assessment, remote trials), clinical trial platform innovation (Bayesian designs, decentralized trials), and real-world evidence generation. This evolution mirrors the broader pharmaceutical industry's pivot from traditional clinical development toward digital endpoints, decentralized trial models, and regulatory-grade real-world data.

Teva is investing in digital clinical endpoints and decentralized trial infrastructure, signaling readiness for partnerships in remote monitoring, digital biomarkers, and regulatory-grade real-world data collection.

How they like to work

Teva participates exclusively as a consortium partner — never as coordinator — in large, multi-partner IMI and RIA consortia. With 280 unique partners across 26 countries from just 11 projects, they operate in very large consortia (averaging 25+ partners per project), typical of IMI public-private partnerships. This positions them as a reliable industry data and expertise contributor rather than a project driver, making them a strong pick when a consortium needs a major pharma company to provide clinical datasets, regulatory insight, or industry validation.

Teva has collaborated with 280 unique partners across 26 countries through large IMI-style consortia, giving them one of the broadest partner networks among pharma participants. Their connections span academic medical centers, SME biotech firms, regulatory bodies, and other large pharma companies across Europe.

What sets them apart

As a top-10 global pharmaceutical company specializing in generics and CNS therapies, Teva brings commercial-scale manufacturing perspective and massive patient datasets that most academic or SME partners cannot match. Their consistent presence in IMI consortia — the EU's flagship public-private health partnerships — signals strong credibility with both regulators and the European research community. For consortium builders, Teva adds immediate industry validation and access to real-world clinical data from one of the world's largest patient-facing pharma operations.

Highlights from their portfolio

• AIMS-2-TRIALS
  One of the largest autism research initiatives globally, running until 2026, combining biomarker discovery with clinical trials for intellectual disability and neurodevelopment.
• EU-PEARL
  Pioneering platform trial methodology with Bayesian statistics and shared data governance — a model that could reshape how multi-arm clinical trials are run in Europe.
• MOBILISE-D
  Bridges digital health and regulatory science by developing digital mobility endpoints validated for conditions including Parkinson's, COPD, and hip fracture recovery.